ArticleBMC cancer2023

Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.

Farastuk Bozorgmehr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.